Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 2 1Phase 1 1

Status

Completed 2Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 9INDUSTRY 5NIH 3

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 5Thoracic 3Genitourinary 1

Conditions

Neoplasms 3216Carcinoma, Non-Small-Cell Lung 2729Breast Neoplasms 2551Colorectal Neoplasms 1463Prostatic Neoplasms 1307Neoplasm Metastasis 1301Multiple Myeloma 1112Melanoma 1103Ovarian Neoplasms 1006Lung Neoplasms 945Recurrence 924Leukemia, Myeloid, Acute 879Pancreatic Neoplasms 833Lymphoma, Non-Hodgkin 767Lymphoma 713Stomach Neoplasms 692Carcinoma, Renal Cell 660Carcinoma, Hepatocellular 647Leukemia, Lymphocytic, Chronic, B-Cell 560Squamous Cell Carcinoma of Head and Neck 550Lymphoma, Follicular 515Head and Neck Neoplasms 490Glioblastoma 473Small Cell Lung Carcinoma 447Lymphoma, Large B-Cell, Diffuse 440Triple Negative Breast Neoplasms 436Advanced Solid Tumors 432Leukemia 426Uterine Cervical Neoplasms 420Urinary Bladder Neoplasms 405

Interventions

pembrolizumab 3relatlimab 1lifileucel 1dabrafenib 1Temozolomide 1Paclitaxel 1Opdualag 1Nivolumab 1Ipilimumab 1Dacarbazine 1Carboplatin 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Melanoma, Cutaneous Malignant × Clear all
NCT06743126 2026-05-29

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting
360 enrolled
Dermatologic

Melanoma, Cutaneous Malignant

NCT05479812 2026-02-09

Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors

Werewolf Therapeutics, Inc.

Phase 1 Active not recruiting
150 enrolled
DermatologicGenitourinaryThoracic

Melanoma, Cutaneous Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms

NCT05585320 2025-09-02

A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

Immuneering Corporation

Phase 1/2 Active not recruiting
209 enrolled
DermatologicThoracic

Melanoma, Cutaneous Malignant, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT06208124 2025-05-28

A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors

Immuneering Corporation

Phase 1/2 Completed
30 enrolled
DermatologicThoracic

Melanoma, Cutaneous Malignant, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT03541148 2018-05-30

Evaluation of Oncoxin-Viusid® in Cutaneous Melanoma

Catalysis SL

Phase 2 Completed
20 enrolled
Dermatologic

Melanoma, Cutaneous Malignant, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡